A Phase 3 interventional study of Delgocitinib in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 95 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.
Among the 13 studies in Eczema by LEO Pharma, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 8th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:
LEO Pharma · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 801 is above the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 178 across the 12 interventional studies, 1,000 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Eczema by LEO Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this extension trial is to evaluate the long-term safety of delgocitinib.
Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36. A final follow-up phone call is planned on Week 38.
Subject who completed 16 weeks of treatment with delgocitinib cream 20 mg/g or vehicle cream twice daily in trials DELTA 1 or DELTA 2 will be offered to roll-over to this extension trial.
Subjects will be treated with delgocitinib cream 20 mg/g twice daily only if they need it to control their chronic hand eczema. In the periods when the disease is controlled, no treatment will be administered.
Clinic visits every 4 weeks are planned (with the possibility of unscheduled visits) to investigate safety and efficacy of treatment, as well as its effect on patient-reported outcomes (PROs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be treated with delgocitinib cream 20 mg/g twice daily as needed.
Drug: Delgocitinib
Delgocitinib cream 20 mg/g
Number of Treatment-emergent Adverse Events From Baseline up to Week 38
An AE will be considered treatment emergent if it started after the baseline visit
Time frame: From baseline up to Week 38
Number of Participants With IGA-CHE Score at Each Scheduled Visit From Baseline up to Week 36
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
Time frame: From baseline up to Week 38
Number of Participants With IGA-CHE Score of 0 (Clear) or 1 (Almost Clear) at Each Scheduled Visit From Baseline up to Week 36.
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
Time frame: From baseline up to Week 38
HECSI Score at Each Scheduled Visit From Baseline up to Week 36
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).
Time frame: From baseline up to Week 38
Number of Participants With HECSI-75 at Each Scheduled Visit From Baseline up to Week 36
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-75 is defined as at least 75% improvement in HECSI score from parent trial baseline.
Time frame: From baseline up to Week 38
Number of Participants With HECSI-90 at Each Scheduled Visit From Baseline up to Week 36
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from parent trial baseline.
Time frame: From baseline up to Week 38
| Milestone | As-needed Treatment With Delgocitinib |
|---|---|
| Started | 801 |
| Completed | 664 |
| Not completed | 137 |
| Withdrew: Adverse event | 7 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 52 |
| Withdrew: Pregnancy | 4 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Lack of efficacy | 55 |
| Withdrew: Various reasons | 9 |
An AE will be considered treatment emergent if it started after the baseline visit
| events | As-needed Treatment With Delgocitinib |
|---|---|
| Number of Treatment-emergent Adverse Events From Baseline up to Week 38 | 1238 |
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
| Participants | As-needed Treatment With Delgocitinib |
|---|---|
| At baseline : 0-Clear | 77 |
| At baseline : 1- Almost Clear | 83 |
| At baseline : 2- Mild | 345 |
| At baseline : 3- Moderate | 243 |
| At baseline : 4- Severe | 53 |
| Week 4 : 0-Clear | 58 |
| Week 4 : 1- Almost Clear | 76 |
| Week 4 : 2- Mild | 436 |
| Week 4 : 3- Moderate | 189 |
| Week 4 : 4- Severe | 28 |
| Week 8 : 0-Clear | 73 |
| Week 8 : 1- Almost Clear | 82 |
| Week 8 : 2- Mild | 413 |
| Week 8 : 3- Moderate | 167 |
| Week 8 : 4- Severe | 25 |
| Week 12 : 0-Clear | 79 |
| Week 12 : 1- Almost Clear | 76 |
| Week 12 : 2- Mild | 414 |
| Week 12 : 3- Moderate | 152 |
| Week 12 : 4- Severe | 18 |
| Week 16 : 0-Clear | 79 |
| Week 16 : 1- Almost Clear | 77 |
| Week 16 : 2- Mild | 407 |
| Week 16 : 3- Moderate | 147 |
| Week 16 : 4- Severe | 13 |
| Week 20 : 0-Clear | 72 |
| Week 20 : 1- Almost Clear | 90 |
| Week 20 : 2- Mild | 401 |
| Week 20 : 3- Moderate | 123 |
| Week 20 : 4- Severe | 19 |
| Week 24 : 0-Clear | 65 |
| Week 24 : 1- Almost Clear | 67 |
| Week 24 : 2- Mild | 415 |
| Week 24 : 3- Moderate | 118 |
| Week 24 : 4- Severe | 15 |
| Week 28 : 0-Clear | 68 |
| Week 28 : 1- Almost Clear | 79 |
| Week 28 : 2- Mild | 408 |
| Week 28 : 3- Moderate | 109 |
| Week 28 : 4- Severe | 8 |
| Week 32 : 0-Clear | 71 |
| Week 32 : 1- Almost Clear | 67 |
| Week 32 : 2- Mild | 395 |
| Week 32 : 3- Moderate | 118 |
| Week 32 : 4- Severe | 12 |
| Week 36 : 0-Clear | 115 |
| Week 36 : 1- Almost Clear | 124 |
| Week 36 : 2- Mild | 300 |
| Week 36 : 3- Moderate | 111 |
| Week 36 : 4- Severe | 13 |
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).
| Participants | As-needed Treatment With Delgocitinib |
|---|---|
| Baseline | 160 |
| Week 4 | 134 |
| Week 8 | 155 |
| Week 12 | 155 |
| Week 16 | 156 |
| Week 20 | 162 |
| Week 24 | 132 |
| Week 28 | 147 |
| Week 32 | 138 |
| Week 36 | 239 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score).
| score on a scale | As-needed Treatment With Delgocitinib |
|---|---|
| Baseline | 30.8 ± 36.5 |
| Week 4 | 24.3 ± 27.2 |
| Week 8 | 21.4 ± 25.3 |
| Week 12 | 20.2 ± 23.9 |
| Week 16 | 17.9 ± 21.1 |
| Week 20 | 17.8 ± 22.5 |
| Week 24 | 17.7 ± 19.6 |
| Week 28 | 16.6 ± 19.0 |
| Week 32 | 16.9 ± 20.0 |
| Week 36 | 15.4 ± 20.6 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-75 is defined as at least 75% improvement in HECSI score from parent trial baseline.
| Participants | As-needed Treatment With Delgocitinib |
|---|---|
| At baseline | 347 |
| Week 4 | 391 |
| Week 8 | 415 |
| Week 12 | 411 |
| Week 16 | 432 |
| Week 20 | 438 |
| Week 24 | 409 |
| Week 28 | 414 |
| Week 32 | 411 |
| Week 36 | 452 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score). HECSI-90 is defined as at least 90% improvement in HECSI score from parent trial baseline.
| Participants | As-needed Treatment With Delgocitinib |
|---|---|
| At baseline | 207 |
| Week 4 | 195 |
| Week 8 | 224 |
| Week 12 | 222 |
| Week 16 | 229 |
| Week 20 | 239 |
| Week 24 | 204 |
| Week 28 | 236 |
| Week 32 | 220 |
| Week 36 | 291 |
Collected over From baseline to week 36. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| As-needed Treatment With Delgocitinib | 3/801 (0.4%) | 27/801 (3.4%) | 329/801 (41.1%) |
| Event | As-needed Treatment With Delgocitinib |
|---|---|
| Hand dermatitisSkin and subcutaneous tissue disorders | 2/801 |
| Myocardial infarctionCardiac disorders | 1/801 |
| Abdominal incarcerated herniaGastrointestinal disorders | 1/801 |
| Abdominal pain upperGastrointestinal disorders | 1/801 |
| Food poisoningGastrointestinal disorders | 1/801 |
| DeathGeneral disorders | 1/801 |
| CholecystitisHepatobiliary disorders | 1/801 |
| CholelithiasisHepatobiliary disorders | 1/801 |
| Contrast media allergyImmune system disorders | 1/801 |
| AppendicitisInfections and infestations | 1/801 |
| Event | As-needed Treatment With Delgocitinib |
|---|---|
| COVID-19Infections and infestations | 134/801 |
| NasopharyngitisInfections and infestations | 128/801 |
| Upper respiratory tract infectionInfections and infestations | 32/801 |
| Hand dermatitisSkin and subcutaneous tissue disorders | 30/801 |
| InfluenzaInfections and infestations | 28/801 |
| HeadacheNervous system disorders | 22/801 |
| Back painMusculoskeletal and connective tissue disorders | 19/801 |
| EczemaSkin and subcutaneous tissue disorders | 17/801 |
| Age, Categorical(Participants) | As-needed Treatment With Delgocitinib |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 735 |
| >=65 years | 66 |
| Age, Continuous(years) | As-needed Treatment With Delgocitinib |
|---|---|
| Mean | 45 ± 14.4 |
| Sex: Female, Male(Participants) | As-needed Treatment With Delgocitinib |
|---|---|
| Female | 512 |
| Male | 289 |
| Ethnicity (NIH/OMB)(Participants) | As-needed Treatment With Delgocitinib |
|---|---|
| Hispanic or Latino | 21 |
| Not Hispanic or Latino | 752 |
| Unknown or Not Reported | 28 |
| Region of Enrollment(participants) | As-needed Treatment With Delgocitinib |
|---|---|
| Canada | 162 |
| Netherlands | 16 |
| Belgium | 19 |
| Denmark | 20 |
| Poland | 180 |
| Italy | 40 |
| United Kingdom | 23 |
| France | 68 |
| Germany | 215 |
| Spain | 58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Sep 2023, 24 months.
Results were first posted in Jan 2025, 1 year 4 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib